Pei-Jane Tsai

Prof. Pei-Jane Tsai

National Cheng Kung University, College of Medicine, Department of Medical Laboratory Science and Biotechnology
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
YHYuan-Pin Hung
Yuan-Pin Hung
JLJen-Chieh Lee
Jen-Chieh Lee
CCChun-Wei Chiu
Chun-Wei Chiu
Ching-Chi LeeChing-Chi Lee
Ching-Chi Lee
PTPei-Jane Tsai
Pei-Jane Tsai
WKWen-Chien Ko
Wen-Chien Ko
Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related hospitalization or death was observed in patients treated with nirmatrelvir/ritonavir within five days of symptom onset. Moreover, good oral availability enables the usage of nirmatrelvir/ritonavir, not only in hospitalized patients, but also among outpatients. Nirmatrelvir (PF-07321332) has been demonstrated to stop the spread of COVID-19 in animal models. Despite frequent mutations in the viral genomes of SARS-CoV-2, nirmatrelvir shows an effective antiviral effect against recent coronavirus mutants. Despite the promising antiviral effect of nirmatrelvir, there are several unresolved concerns. First, the final results of large-scale clinical trials for early therapy of mild cases of COVID-19 are not yet published. Second, the effectiveness of nirmatrelvir against upcoming variants in the coming years requires close monitoring. Considering the promising preliminary results of the EPIC-HR trial, nirmatrelvir/ritonavir in conjunction with vaccines and non-pharmacological interventions, may represent the dawn in the dark of the COVID-19 pandemic.

1 June 2015 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Closed access
YHYuan-Pin Hung
Yuan-Pin Hung
JLJen-Chieh Lee
Jen-Chieh Lee
HLHsiao-Ju Lin
Hsiao-Ju Lin
HLHsiao-Chieh Liu
Hsiao-Chieh Liu
YWYi-Hui Wu
Yi-Hui Wu
WKWen-Chien Ko
Wen-Chien Ko

25 July 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YHYuan-Pin Hung
Yuan-Pin Hung
HLHsiao-Ju Lin
Hsiao-Ju Lin
TWTai-Chieh Wu
Tai-Chieh Wu
HLHsiu-Chuan Liu
Hsiu-Chuan Liu
JLJen-Chieh Lee
Jen-Chieh Lee
WKWen-Chien Ko
Wen-Chien Ko
This study is to investigate the significance and risk factors of fecal toxigenic (tCdC) or non-toxigenic Clostridium difficile colonization (ntCdC) among hospitalized patients. Adults admitted to medical wards in a district hospital between January 2011 and June 2012 were enrolled, and those with a history of colectomy, C. difficile fecal colonization or infection or receipt of either metronidazole or oral vancomycin within 3 months, were excluded. Stools collected within 48 hours after admission and every week during hospitalization were cultured for C. difficile. Among the 441 enrolled patients, 84 (20.0%) had CdC at initial screening, including 58 (13.2%) with tCdC and 26 (6.8%) with ntCdC. Among patients with initial negative fecal screening for CdC, it took an average of 70.6 days or 66.5 days to develop tCdC or ntCdC during the study period. Finally 78 (17.7%) had tCdC and 34 (7.7%) had ntCdC. During the follow-up period, the patients with tCdC had a higher risk of CDAD (11/79, 14.1%) than those without CdC (3/328, 0.9%) and those with ntCdC (0/34, 0%) (P<0.001). In multivariate analysis, the TLR4 rs1927914 polymorphism (GG genotype) (odds ratio [OR] 4.4, 95% confidence interval [CI] 1.6–11.8, P = 0.003) and recent cefepime therapy (OR 5.3, 95% CI 2.1–13.2, P<0.001) were independently associated with tCdC, whereas recent cefuroxime (OR 11.7, 95% CI 2.3–60.2, P = 0.003) and glycopeptide therapy (OR 10.9, CI: 2.1–57.2, P = 0.005) associated with ntCdC. The incidence of CDAD is highest in patients with tCdC and lowest in patients with ntCdC, and the TLR4 rs1927914 polymorphism GG genotype and recent cefepime therapy were independently associated with tCdC.

1 April 2015 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Closed access
HLHsiao-Ju Lin
Hsiao-Ju Lin
YHYuan-Pin Hung
Yuan-Pin Hung
HLHsiu-Chuan Liu
Hsiu-Chuan Liu
JLJen-Chieh Lee
Jen-Chieh Lee
CLChih-I Lee
Chih-I Lee
WKWen-Chien Ko
Wen-Chien Ko

24 March 2015 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
YHYuan-Pin Hung
Yuan-Pin Hung
WKWen-Chien Ko
Wen-Chien Ko
PCPo-Han Chou
Po-Han Chou
YCYi-Hsuan Chen
Yi-Hsuan Chen
HLHsiao-Ju Lin
Hsiao-Ju Lin
PTPei-Jane Tsai
Pei-Jane Tsai
Background. Clostridium difficile is currently the leading cause of infectious diarrhea in hospitalized patients. In addition to the infection due to toxigenic C. difficile in the gastrointestinal tract of susceptible hosts, other predisposing factors for C. difficile infection (CDI) are identified, including advanced age, a prolonged hospital stay, and use of acid-suppressive drugs. Of note, exposure to gastric acid-reducing agents, such as H2 blockers and proton pump inhibitors (PPIs), remains a controversial risk factor, and has been associated with CDI in some studies but not in others. A mouse model of antibiotic-associated clostridial colitis was established to examine the role of PPIs for CDI. Materials and Methods. A mouse model of antibiotic-associated clostridial colitis was set up. NF-κB reporter mice were used to address the in vivo spatial and temporal inflammatory patterns of C. difficile–associated colitis. Serum levels of lipopolysaccharide and dextran-FITC were measured to reflect the barrier permeability of affected intestines. Results. Mice with CDI that were exposed to PPI exhibited greater losses of stool consistency and body and cecal weights than those that were not exposed to PPI. Further, more neutrophilic infiltrations, epithelial damage, and inflammatory cytokine expression were noted in colon specimens of the mice with PPI exposure. More-evident inflammatory responses were detected by in vivo imaging of NF-κB reporter mice with CDI that were exposed to PPI. Gut barrier permeability was increased to a greater extent, as reflected by higher serum levels of lipopolysaccharide and dextran-FITC in mice with CDI that were exposed to PPI. Conclusions. Our mouse model demonstrates that PPI exposure increases the severity of intestinal inflammation in mice with C. difficile–associated colitis.

28 July 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
YHYuan-Pin Hung
Yuan-Pin Hung
Ching-Chi LeeChing-Chi Lee
Ching-Chi Lee
JLJen-Chieh Lee
Jen-Chieh Lee
PTPei-Jane Tsai
Pei-Jane Tsai
WKWen-Chien Ko
Wen-Chien Ko
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus of the family Coronaviridae, causes coronavirus disease 2019 (COVID-19), an influenza-like disease that chiefly infects the lungs through respiratory transmission. The spike protein of SARS-CoV-2, a transmembrane protein in its outer portion, targets angiotensin-converting enzyme 2 (ACE2) as the binding receptor for the cell entry. As ACE2 is highly expressed in the gut and pulmonary tissues, SARS-CoV-2 infections frequently result in gastrointestinal inflammation, with presentations ordinarily ranging from intestinal cramps to complications with intestinal perforations. However, the evidence detailing successful therapy for gastrointestinal involvement in COVID-19 patients is currently limited. A significant change in fecal microbiomes, namely dysbiosis, was characterized by the enrichment of opportunistic pathogens and the depletion of beneficial commensals and their crucial association to COVID-19 severity has been evidenced. Oral probiotics had been evidenced to improve gut health in achieving homeostasis by exhibiting their antiviral effects via the gut–lung axis. Although numerous commercial probiotics have been effective against coronavirus, their efficacies in treating COVID-19 patients remain debated. In ClinicalTrials.gov, 19 clinical trials regarding the dietary supplement of probiotics, in terms of Lactobacillus and mixtures of Bifidobacteria and Lactobacillus, for treating COVID-19 cases are ongoing. Accordingly, the preventive or therapeutic role of probiotics for COVID-19 patients can be elucidated in the near future.